Articles tagged with Withdrawal Symptoms
A randomized clinical trial found symptom-based dosing decreases discharge time compared to scheduled opioid taper approaches among infants with opioid withdrawal. This approach, using Eat, Sleep, Console, led to faster recovery and improved outcomes.
A new study highlights how geography and regulations limit methadone access in US jails, with over half of facilities located more than a 30-minute drive from the nearest opioid treatment program. This distance creates logistical challenges for providing this lifesaving medication to incarcerated individuals.
Researchers at NIH have identified a novel opioid compound that shows potential as a therapy for both pain and opioid use disorder. The new drug, called DFNZ, has high pain-relieving effects without causing respiratory depression or addiction.
A new overview of systematic reviews found that nicotine-containing e-cigarettes are more effective for smoking cessation than other interventions. The review also identified gaps in current evidence, including the need for high-quality studies on cytisine and bupropion.
A new study published in JAMA found that emergency department-initiated buprenorphine for opioid use disorder was well-tolerated and effective, with a low risk of withdrawal. The 7-day extended-release and sublingual buprenorphine groups showed similar treatment engagement rates on day 7.
A new study found that varenicline, a medication used to quit smoking, can help men with cannabis use disorder reduce their cannabis use. However, the same treatment showed no significant effect on female participants. Women who received varenicline reported higher withdrawal and craving scores and lower medication adherence compared t...
This randomized clinical trial found yoga to significantly accelerate opioid withdrawal recovery and improve autonomic regulation, anxiety, sleep, and pain. The study supports the integration of yoga into withdrawal protocols as a neurobiologically informed intervention addressing core regulatory processes.
Researchers found that abstinent smokers have altered brain activity linked to increased pain sensitivity and a need for more postoperative pain relief. The study suggests that nicotine withdrawal affects specific brain regions, leading to higher requirements for pain management in surgery.
A new study found that nearly half of patients discharged with take-home methadone successfully connected to treatment within 72 hours. The likelihood of successful follow-up increased if patients were already enrolled in an OTP or received higher methadone doses.
A new study suggests that psychological cessation fatigue is a key factor in smoking relapse among ex-smokers. The study found that exhaustion from constantly trying to remain a non-smoker can overwhelm coping skills and motivation, leading to increased risk of relapse.
A new study by Scripps Research scientists reveals that a small midline brain region plays a key role in how animals learn to continue drinking to avoid withdrawal symptoms. This brain pathway is responsible for driving strong relapse behavior, making it a crucial target for developing new treatments for substance use disorders.
A nationwide study found that alcohol withdrawal syndrome significantly increases risks of complications and longer hospital stays after major surgery. Proactive screening and multidisciplinary care can help prevent such complications.
Researchers found that mice with weakened laterodorsal tegmentum responses exhibited reduced withdrawal symptoms and increased interactions with new objects. The interpeduncular nucleus inhibits the LDTg, suggesting a potential target for nicotine addiction treatments.
A WVU microbiology student has discovered a new species of fungus, Periglandula clandestina, that produces effects similar to the semisynthetic drug LSD. The fungus is highly efficient at making ergot alkaloids, which can be used therapeutically to treat conditions like depression and addiction.
A new study found that people taking antidepressants for over two years are more likely to experience withdrawal symptoms, including anxiety and fatigue. Long-term users also tend to have worse withdrawal symptoms and are less able to stop taking the medication.
Research suggests that heavy drinkers may experience long-lasting sensitivity to mechanical stimuli, leading to permanent allodynia. The study identified a potential drug target, endocannabinoid 2-AG metabolism, for treating neuropathic pain associated with chronic and excessive alcohol consumption.
Hospitalizations involving alcohol withdrawal syndrome (AWS) are a significant concern, especially in high-risk individuals. The study found that AWS burden is comparable to complications of other chronic diseases.
A new review of evidence has found that buprenorphine-precipitated withdrawal occurs in only 0-13.2% of adults taking their first dose, with symptoms being generally mild. The study calls for better evidence to measure the true risk and encourages doctors and patients to use this effective treatment.
A pilot study found that ultra-low-dose ketamine can reduce or eliminate withdrawal symptoms associated with quitting fentanyl, enabling patients to transition to buprenorphine treatment. The treatment was successful in 16 out of 37 patients who completed the transition, with 92% remaining in treatment for at least 30 days.
Researchers at the University of Calgary are conducting a clinical trial using probenecid, an anti-gout medication, to treat debilitating opioid withdrawal symptoms. The study's lead authors aim to develop a potential treatment for the disabling symptoms of opioid withdrawal, which can be crippling.
Researchers at UTEP will investigate how stress from nicotine withdrawal is intensified by ovarian hormones in women, aiming to develop more effective treatments for women experiencing severe nicotine withdrawal symptoms. The five-year study will also explore the impact of e-cigarette use on adolescent females.
Researchers have identified a novel compound that can reverse the lethal effects of opioid overdose when paired with naloxone, reducing withdrawal symptoms and extending protection. The discovery builds on new insights into opioid receptors and could combat the devastating fentanyl epidemic.
Researchers have identified a potential compound that enhances naloxone's effectiveness in reversing opioid overdoses by making it more potent and longer-lasting. The compound, dubbed compound 368, was found to improve naloxone's ability to counteract opioid overdoses in mice and enable reversal at lower doses.
A systematic review and meta-analysis of over 20,000 patients found that one in six to seven patients will experience discontinuation symptoms directly caused by stopping the medication. Severe symptoms occurred in about 3% of patients, with certain antidepressants increasing the risk.
Starting people with opioid use disorder on extended-release, injectable naltrexone within five to seven days of seeking treatment is more effective than the standard method. This rapid treatment protocol requires closer medical supervision and could make XR-naltrexone a more viable option for treating opioid use disorder.
Researchers have found that LY2444296, a compound blocking the kappa opioid receptor, significantly reduced withdrawal symptoms and alcohol consumption in rats with alcohol dependence. The study suggests that blocking this receptor could lead to new treatment options for people experiencing alcohol use disorder.
Persistent withdrawn and somatic symptoms in adolescence increase the risk of suicidal thoughts in mid-adolescence. The study found that these symptoms persist or increase over time to be particularly concerning for suicidal risk.
New research suggests people can experience emotional and social difficulties, as well as changes in their thinking patterns, when stopping antidepressants like Prozac. This is especially true for sudden stops or inadequate supervision by a doctor.
Mobile methadone units show significant impact in expanding opioid treatment access in rural areas, with a 13-point increase in Medication for Opioid Use Disorder (MOUD) treatment rates. Adding units exclusively to rural Louisiana provides nearly 20% of beneficiaries within 24 miles of a provider.
A comprehensive global analysis found that these stop-smoking aids are nearly twice as effective as single forms of NRT. Dual forms of NRT, such as combining a patch with gum or a lozenge, were found to be nearly as effective as nicotine e-cigarettes and prescription medications.
A new study suggests that treating insomnia can prevent opioid relapse in rats, and potentially in humans. The experimental insomnia drug DORA-12 reduced withdrawal symptoms and prevented drug-seeking behavior in rats experiencing oxycodone withdrawal.
A new study published in JAMA Network Open shows that methadone use following surgery in infants can increase hospital stay and delay recovery. Babies who required methadone needed to stay in the hospital an average of 21 days longer after surgery, as well as more days on ventilators and IV nutrition.
A new study shows that earlier transfer to specialized care is associated with better outcomes for infants with NOWS, including shorter hospital stays and less exposure to medication. The study found that nonpharmacologic interventions, such as swaddling and pacifier use, are critical to clinical outcomes.
The University of Sydney-led guidelines recommend personalized deprescribing plans and gradual dose reduction to minimize withdrawal symptoms. Clinicians should avoid abruptly stopping opioids without support or pain management plans, especially for patients with severe opioid use disorder.
A new study from Boston Medical Center found that offering medications for opioid addiction in jails leads to a significant decrease in overdose deaths. Treating opioid addiction during incarceration is also cost-effective and saves lives.
A new Northwestern Medicine study found that only 7% of Medicaid enrollees with opioid use disorder (OUD) received residential treatment, highlighting a significant gap in care. Residential treatment centers provide structured support and are considered one of the best treatments for severe substance use.
A multi-site NIH study shows that less than 1% of people with opioid use disorder experience withdrawal when starting buprenorphine in the emergency department. The findings provide strong evidence for safe and effective buprenorphine treatment, even for those using stronger opioids like fentanyl.
A study published in Tobacco Control found that alternatives to menthol cigarettes pose significant addiction and health risks. Mentholated pipe tobacco and tubes were the most appealing and addictive options, suggesting they should be included in the proposed ban.
A telemedicine program for opioid use disorder patients showed that 55% of patients continued with their medication 30 days after being prescribed buprenorphine. The program received 371 calls and provided 249 buprenorphine prescriptions, filling a significant gap in treatment for this population.
A Washington State University pilot study showed that home sensors can accurately monitor overnight restlessness and sleep problems in people recovering from opioid use disorder. The sensors matched other monitoring methods about 89% of the time, validating patients' concerns about their disturbed sleep.
Physicians recognize benzodiazepine dependence as a significant contributor to the opioid crisis, coined a new term CPBD. Long-term treatment can lead to severe withdrawal symptoms and recurrence of underlying anxiety and insomnia.
A Rutgers University study found that expanding prison opioid treatment programs could reduce the risk of overdose and death among ex-inmates. The researchers suggest that further education on post-release opioid risks is necessary to increase participation in these programs.
A pair of studies published by Washington State University scientists found that hyperbaric oxygen therapy can help individuals with opioid addiction reduce their methadone dose and better manage pain and withdrawal symptoms. The treatment involves breathing pure oxygen in a pressurized environment, resulting in significant dose reduct...
A University of South Florida study suggests targeting kappa-opioid receptors may alleviate working memory deficits and improve executive function in individuals with severe alcohol use disorder. A compound blocking these receptors alleviated working memory deficits and restored normal executive function.
Researchers found that exposure to addiction medicine consult teams led to a significantly reduced risk of death within three months of discharge. Medication played a key role in reducing mortality for patients with opioid use disorders, while other components may be crucial for those with alcohol use disorder.
A study found that the first day of quitting smoking is harder for women than men, particularly in low- and middle-income countries. Women also have more difficulty maintaining long-term abstinence, with larger health warning labels on cigarette packs associated with reduced odds of one-day relapse among them.
A review suggests that doctors should prescribe fewer antidepressants and for shorter periods due to the potential severity and duration of withdrawal symptoms. The use of antidepressants is also associated with a range of side effects, but clinical trial data often don't assess outcomes that matter most to patients.
Experts suggest expanding treatment options for hospital patients with opioid withdrawal symptoms, potentially allowing more individualized and patient-centered care. Randomized controlled trials are needed to determine the efficacy of short-acting opioids in this context.
Research in mice reveals that drug withdrawal alters brain activity patterns, causing increased functional connectivity and decreased modularity. This universal effect may be a common trait among different types of addictive drugs.
A new study recommends making methadone more widely available through office-based visits with primary care physicians to improve access and convenience for patients with opioid use disorder. This could reduce transportation costs and enhance treatment retention rates, but further research is needed to confirm its effectiveness.
A new study highlights the urgent need for more research on safe approaches to discontinuing antidepressant treatment. Long-term use can lead to adverse events, but the current low-certainty evidence makes it difficult to determine the best tapering strategies.
A new study found that more than half of people using cannabis for pain experience clusters of multiple withdrawal symptoms when they're between uses. About 10% of patients experienced worsening changes in sleep, mood, mental state, energy, and appetite over two years.
Researchers at Yale University found that prazosin significantly reduced withdrawal symptoms in patients with severe alcohol use disorder. The study showed that patients who received prazosin had fewer heavy drinking episodes and days of drinking compared to those who received a placebo.
A new measure of patient frailty could improve accuracy, fairness, and equity in Medicare value-based payment models. Researchers found that incorporating this measure into cost prediction improved performance, especially among frail patients.
A new study published in Drug and Alcohol Dependence reveals that experiencing opioid withdrawal increases the likelihood of needle sharing and non-fatal overdose among individuals who inject drugs. The research also highlights the urgent need for medication-assisted treatment to address this public health issue.
A new drug has been shown to reduce cannabis withdrawal symptoms and increase abstinence in those trying to quit, according to a Yale-led study. The medication works by inhibiting the enzyme that degrades anandamide, a brain chemical that acts on brain cannabis receptors.
A study by Penn State researchers found that there are five distinct classes of people with alcohol use disorder, each characterized by specific symptoms. Young adults were more likely to fit the profile with excessive drinking and withdrawal symptoms, while older adults struggled with cutting back on their drinking.
A new study finds that 12% of frequent marijuana smokers experienced Cannabis Withdrawal Syndrome, including symptoms like nervousness, hostility, and sleep difficulty. The study also links CWS to psychiatric disorders, mental disability, and a family history of depression.
A systematic review found that serotonin-noradrenaline reuptake inhibitors can cause withdrawal symptoms when discontinued, with venlafaxine showing higher prevalence rates. These symptoms typically occur within a few days of stopping the medication and can last several weeks.
A mouse study found that metformin blocks symptoms of nicotine withdrawal in rodents, eliminating anxiety and negative effects. The diabetes drug appears to activate AMPK, a pathway stimulated by chronic nicotine use, reducing withdrawal symptoms.